An analysis of overall survival in patients who have undergone lung metastasectomy operations for lung metastases of colorectal cancers and malignancies other than colorectal cancer

Basit Öğe Kaydı
dc.authoridkaramustafaoglu, yekta altemur/0000-0002-5491-1219
dc.authoridYANIK, FAZLI/0000-0002-8931-5329
dc.authorwosidkaramustafaoglu, yekta altemur/S-9512-2019
dc.contributor.authorYanik, Fazli
dc.contributor.authorKaramustafaoglu, Yekta Altemur
dc.contributor.authorYoruk, Yener
dc.date.accessioned2024-06-12T10:58:08Z
dc.date.available2024-06-12T10:58:08Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: To compare the survival and factors affecting survival between patient groups with primary colorectal cancers and malignancies other than colorectal cancer, who underwent curative pulmonary metastasectomy Design: Retrospective study Setting: Trakya University School of Medicine, Edirne, Turkey Subjects: Forty-four cases who underwent curative metastasectomy in our clinic between January 2006 and August 2015 Interventions: Primary colorectal cancers (Group 1 = 14 cases), malignancies other than colorectal cancer (Group 2 = 30 cases) Main outcome measure(s): Age, gender, type of primary malignity, disease-free survival, adjuvant therapy, number of radiological nodules, number and type of operations, number and site of nodules resected, presence of relapse, and mean survival Results: Two cases (4.7%) underwent lobectomy, and a total of 123 nodules were excised in 38 cases (86.3%) using thoracotomy and in four cases (9%) using video thoracoscopic surgery. The median survival value was 33 +/- 5.4 months (range:22.2 - 43.7 months) in Group 1, and 28 +/- 6.8 months (range:14.5 - 41.4 months) in Group 2; the cumulative value was 33 +/- 3.7 months (range:25.6 - 40.3 months). Survival did not differ significantly between the groups (p=0.738). Age (p=0.81), gender (p=0.35), disease-free survival (p=0.24), number of metastatic nodules (p=0.60), presence of synchronous-metachronous tumor (p=0.94), adjuvant chemotherapy (p=0.96), adjuvant radiotherapy (p=0.86), and relapse of disease (p=0.07) were not significantly correlated with survival. Conclusion: Survival and factors that affected survival did not differ significantly between the two groups that underwent metastasectomy. It was indicated that the primary tumor is not an effective factor in the selection of patients who would undergo metastasectomy.en_US
dc.identifier.endpage355en_US
dc.identifier.issn0023-5776
dc.identifier.issue4en_US
dc.identifier.startpage351en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19955
dc.identifier.volume51en_US
dc.identifier.wosWOS:000503192700004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKuwait Medical Assocen_US
dc.relation.ispartofKuwait Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal Tumorsen_US
dc.subjectLung Tumorsen_US
dc.subjectMetastasisen_US
dc.subjectLong-Term Survivalen_US
dc.subjectSurgical Resectionen_US
dc.titleAn analysis of overall survival in patients who have undergone lung metastasectomy operations for lung metastases of colorectal cancers and malignancies other than colorectal canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu